- Home
- TIXT vs NTLA Comparison
TIXT vs NTLA Comparison
Compare TIXT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIXT
- NTLA
- Stock Information
- Founded
- TIXT 2005
- NTLA 2014
- Country
- TIXT Canada
- NTLA United States
- Employees
- TIXT N/A
- NTLA N/A
- Industry
- TIXT EDP Services
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TIXT Technology
- NTLA Health Care
- Exchange
- TIXT Nasdaq
- NTLA Nasdaq
- Market Cap
- TIXT 1.0B
- NTLA 1.2B
- IPO Year
- TIXT 2021
- NTLA 2016
- Fundamental
- Price
- TIXT $3.87
- NTLA $10.90
- Analyst Decision
- TIXT Hold
- NTLA Buy
- Analyst Count
- TIXT 9
- NTLA 20
- Target Price
- TIXT $3.77
- NTLA $32.30
- AVG Volume (30 Days)
- TIXT 729.2K
- NTLA 5.0M
- Earning Date
- TIXT 08-01-2025
- NTLA 08-07-2025
- Dividend Yield
- TIXT N/A
- NTLA N/A
- EPS Growth
- TIXT N/A
- NTLA N/A
- EPS
- TIXT N/A
- NTLA N/A
- Revenue
- TIXT $2,718,000,000.00
- NTLA $52,857,000.00
- Revenue This Year
- TIXT $4.29
- NTLA N/A
- Revenue Next Year
- TIXT $3.32
- NTLA N/A
- P/E Ratio
- TIXT N/A
- NTLA N/A
- Revenue Growth
- TIXT 2.03
- NTLA 14.99
- 52 Week Low
- TIXT $2.13
- NTLA $5.90
- 52 Week High
- TIXT $4.60
- NTLA $24.16
- Technical
- Relative Strength Index (RSI)
- TIXT 54.74
- NTLA 45.06
- Support Level
- TIXT $3.55
- NTLA $10.57
- Resistance Level
- TIXT $4.04
- NTLA $11.51
- Average True Range (ATR)
- TIXT 0.13
- NTLA 0.69
- MACD
- TIXT -0.01
- NTLA -0.26
- Stochastic Oscillator
- TIXT 52.85
- NTLA 10.44
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.